Jupiter Endovascular key facts
as of Oct 2026- Developer of catheter technology designed to bring control and precision to catheter interventions.
- Jupiter Endovascular is valued at approximately $96.0M as of Oct 2026 (last reported valuation).
- It has raised $60.8M; the latest was Early Stage VC ($40.0M) in Oct 2025.
- Notable investors include InterVest, LB Investment, Mighty Capital, Sonder Capital Management, SCP Ventures — 6 tracked in total.
- Status: Privately Held (backing).
Jupiter Endovascular's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch Jupiter Endovascular: the Monday email on marks, rounds and moves
Jupiter Endovascular funding rounds
No funding rounds for Jupiter Endovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Jupiter Endovascular
6Jupiter Endovascular valuation
Jupiter Endovascular's last reported valuation was $96 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Jupiter Endovascular investors
6 investors are on record for Jupiter Endovascular, including InterVest, LB Investment, Mighty Capital and Sonder Capital Management.
About Jupiter Endovascular
Developer of catheter technology designed to bring control and precision to catheter interventions. The company's technology mimics the precision and control of direct surgical access in catheter therapies, enabling healthcare professionals to overcome the limitations of catheters.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2024
- Employees
- 42
- Website
- jupiterendo.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.